BC
TXG icon

Bridgefront Capital’s 10x Genomics TXG Stock Holding History

Bridgefront Capital’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24,431
Closed -$286K – 787
2025
Q3 		$286K Buy
+24,431
New +$319K 0.08% 412
2024
Q4 		– Sell
-12,834
Closed -$290K – 789
2024
Q3 		$290K Buy
+12,834
New +$265K 0.11% 330
2024
Q2 		– Sell
-10,285
Closed -$386K – 663
2024
Q1 		$386K Buy
+10,285
New +$452K 0.29% 120
2021
Q1 		– Sell
-3,307
Closed -$468K – 926
2020
Q4 		$468K Buy
+3,307
New +$480K 0.16% 230

Other funds holding TXG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgefront Capital's TXG Position: Q4 2025 in Review

Bridgefront Capital sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 24,431 shares — an estimated $286K sold.

Bridgefront Capital first reported a position in TXG in Q4 2020 and held it in 4 quarters. The position peaked at $468K in Q4 2020. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

  • Bridgefront Capital reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
  • Bridgefront Capital sold 24,431 10x Genomics shares in Q4 2025, an estimated $286K.
  • Bridgefront Capital first reported a position in 10x Genomics in Q4 2020 and held it in 4 quarters.
  • Bridgefront Capital's 10x Genomics position peaked at $468K in Q4 2020.
  • 322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on Bridgefront Capital's 13F filing for Q4 2025, filed 13 Feb 2026.